Search

Filter:

Search Results

MannKind gets out the ax (again) as Afrezza sales fizzle; Bristol-Myers gains new Opdivo/Yervoy approval at the FDA;

vaccine trial.  Story > BiondVax, EU's UNISEC team up for universal flu jab PhIIb.  More > PRA Health joins with clinical research network to improve vaccine studies.  Item > NewLink wins $26.1M ...

Wright, Tornier merger completes; NovoCure kicks IPO investor shares out, reduces to $176M;

with first-in-human vaccine trial.  Story > BiondVax, EU's UNISEC team up for universal flu jab PhIIb.  More > PRA Health joins with clinical research network to improve vaccine studies.  Item > NewLink ...

GSK completes Novartis vaccines purchase; Galena announces positive PhIIb cancer vax results;

of Rochester Medical Center received $3.1 million from the NIH to look for new ways to develop an HIV vaccine ...

PRA Health joins with clinical research network to improve vaccine studies

solutions to smarter vaccine development," AMR CEO Brenda Atchison said in a statement. Release ...

Focusing on neoantigens, Neon Therapeutics launches with a $55M Series A

of existing approaches." Though cancer vaccines have seen their fair share of troubles--evidenced ...

PRA partners up to accelerate vaccine R&D

can help sponsors get vaccines to the people who need them." Together, the companies will focus on small to midsize vaccine trials, PRA said, and the CRO is touting its new partner's 98% subject ...

Patheon rebrands with a $100M IPO in the works

is preparing to take the company public and sell off some of its stake. In a June filing with the SEC, ...

Will a desktop device that synthesizes lidocaine revolutionize pharma manufacturing?

delivers painkiller to second layer of skin in 5 seconds Market research firm says needle-free vaccine ...

Healthcare IPO outlook in Singapore dims; Takeda gets MHLW Leuplin nod;

to buy Beijing Wanter Bio's P. aeruginosa vaccine, which is aimed at fighting the spread ...

Third Rock lights up Neon with next-wave cancer R&D strategy and $55M

for off-the-shelf therapeutic vaccines, looking for antigens that are shared across groups of patients. The next ...